Table 1.
Baseline characteristics
| Presymptomatic D-CAA n = 28 |
Symptomatic D-CAA n = 29 |
Sporadic CAA n = 59 |
Controls < 55y n = 33 |
Controls ≥ 55y n = 38 |
|
|---|---|---|---|---|---|
| Age, y, mean (range) | 40.4 (27–55) | 58.1 (43–74) | 71.7 (57–86) | 42.4 (27–54) | 64.8 (55–85) |
| Women, n (%) | 18 (64.3) | 14 (48.3) | 25 (42.4) | 16 (48.5) | 14 (36.8) |
| Education > 12y, n (%) | 19 (67.9) | 12 (41.4) | 37 (62.7)a | - | - |
| Previous symptomatic ICH, n (%) | - | 29 (100) | 30 (50.8) | - | - |
| Time between ICH and blood/CSF withdrawal in months, median (range) | - | 22 (2–85) | 14 (2–87) | - | - |
| Cognitive testing performed, n (%) | 28 (100) | 29 (100) | 51 (86.4) | - | - |
| MoCA, median (range) | 28 (24-30) | 27 (15-30) | 25.5 (8-30)b | - | - |
| MRI data available, n (%) | 25 (89.3) | 27 (93.1) | 55 (93.2) | - | - |
| Macrobleed count, median (range) | 0 (0–0) | 4 (1-26) | 0 (0–13) | - | - |
| CAA CSVD score, median (range) | 1 (0–4) | 4 (3-60 | 4 (0–6) | - | - |
| CSF Aβ40 (pg/mL), median (range)c | 2184 (832–3752) | 1733.5 (910–2702) | 6125 (1642–12,029) | 7551.5 (2889–14,874) | 9036 (3905–16,305) |
| CSF Aβ42 (pg/mL), median (range)d | 102 (41–184) | 76 (41–106) | 312.5 (72–1088) | 629 (233–1578) | 681 (326–1265) |
| CSF p-tau (pg/mL), median (range)e | - | - | 45.2 (24.5–207.1) | 22.9 (11–49) | 33.8 (18–94.7) |
Abbreviations: Aβ = β-amyloid, CAA Cerebral amyloid angiopathy, CSF Cerebrospinal fluid, CSVD Cerebral small vessel disease, D-CAA Dutch cerebral amyloid angiopathy, GFAP Glial fibrillary acidic protein, ICH Intracerebral hemorrhage, MoCA Montreal Cognitive Assessment, NFL Neurofilament light, p-tau phosphorylate tau, y years
a Missing data in 4 participants, b missing data in 8 participants
c, d Presymptomatic participants with D-CAA n = 11, symptomatic participants with D-CAA n = 12, sCAA participants n = 28, controls < 55 n = 32, controls ≥ 55 n = 21
e sCAA participants = 19, controls < 55 n = 31, controls ≥ 55 n = 21